Whitespace Analysis

Find crowded markets, emerging opportunities, and underserved indications by trial activity and sponsor concentration.

Limited-time launch pricing

$99/month

30-day free trial - no credit card

Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.

Competitive Density Analysis

Data updated: Sep 20, 2026

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication	TA	Active Trials	Phase 3	Phase 2	Sponsors
Solid Tumor (Advanced)	Oncology	3633	399	1828	803
Non-Hodgkin Lymphoma	Oncology	1679	189	1070	229
Breast Cancer	Oncology	1568	340	927	198
NSCLC	Oncology	1510	290	908	329
Colorectal Cancer	Oncology	1189	198	749	239
Prostate Cancer	Oncology	895	167	522	154
AML	Oncology	715	84	372	121
Multiple Myeloma	Oncology	697	119	397	89
Pancreatic Cancer	Oncology	690	78	424	202
Hepatocellular Carcinoma	Oncology	643	96	389	122
Obesity	Metabolic	577	152	178	98
Hematologic Malignancies	Oncology	567	61	328	83
Ovarian Cancer	Oncology	565	93	297	167
Lung Cancer (General)	Oncology	563	80	338	105
Head and Neck Cancer	Oncology	548	58	345	150

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication	TA	Phase 3	% of Trials	Active	Sponsors
Solid Tumor (Advanced)	Oncology	399	11%	3633	803
Breast Cancer	Oncology	340	22%	1568	198
NSCLC	Oncology	290	19%	1510	329
Colorectal Cancer	Oncology	198	17%	1189	239
Non-Hodgkin Lymphoma	Oncology	189	11%	1679	229
Prostate Cancer	Oncology	167	19%	895	154
Stroke	Cardiovascular	164	42%	388	55
Obesity	Metabolic	152	26%	577	98
Multiple Myeloma	Oncology	119	17%	697	89
Acute Pain	Pain	102	24%	421	40
Hypertension	Cardiovascular	100	29%	343	93
Hepatocellular Carcinoma	Oncology	96	15%	643	122

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication	TA	Trials/Sponsor	Active	Sponsors
H. pylori	Infectious Disease	19.7	59	3
HIV	Infectious Disease	17.7	319	18
Chronic Pain	Pain	17	68	4
Postoperative Pain	Pain	16.2	194	12
PTSD	CNS	14.7	88	6
Sepsis	Infectious Disease	14.1	113	8
Alcohol Use Disorder	CNS	13.9	111	8
Opioid Use Disorder	CNS	13.9	125	9
Atrial Fibrillation	Cardiovascular	12.1	133	11
Acute Pain	Pain	10.5	421	40

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication	TA	Sponsors	Active	Phase 3
Solid Tumor (Advanced)	Oncology	803	3633	399
NSCLC	Oncology	329	1510	290
Colorectal Cancer	Oncology	239	1189	198
Non-Hodgkin Lymphoma	Oncology	229	1679	189
Pancreatic Cancer	Oncology	202	690	78
Breast Cancer	Oncology	198	1568	340
Ovarian Cancer	Oncology	167	565	93
Prostate Cancer	Oncology	154	895	167
Head and Neck Cancer	Oncology	150	548	58
Melanoma	Oncology	142	521	63

Showing top indications in each category

Upgrade to Pro for full competitive density analysis across 151 indications

See Pro Features

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2008+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.